Provided by Tiger Trade Technology Pte. Ltd.

Acumen Pharmaceuticals, Inc.

3.16
-0.0300-0.94%
Post-market: 3.220.0632+2.00%19:30 EDT
Volume:716.03K
Turnover:2.32M
Market Cap:228.19M
PE:-1.93
High:3.34
Open:3.21
Low:3.14
Close:3.19
52wk High:3.60
52wk Low:1.21
Shares:72.21M
Float Shares:37.05M
Volume Ratio:1.45
T/O Rate:1.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6370
EPS(LYR):-2.0035
ROE:-120.50%
ROA:-45.77%
PB:3.98
PE(LYR):-1.58

Loading ...

Acumen Pharma director Derrell Porter disposes of USD 45,128 in common shares

Reuters
·
Jun 18

BRIEF-JCR Says Acumen Exercises Exclusive Option For Up To Two Alzheimer's Candidates

Reuters
·
Jun 18

JCR announces Acumen exercises exclusive option for Alzheimer’s candidates

TIPRANKS
·
Jun 18

Jcr Pharmaceuticals Co - to Receive Tiered Royalties on Net Sales From Collaboration Products

THOMSON REUTERS
·
Jun 18

Jcr Pharmaceuticals Co - Eligible for up to $555 Mln in Milestone Payments From Acumen Deal

THOMSON REUTERS
·
Jun 18

Acumen Pharmaceuticals Nominates 2 Drug Candidates to Treat Alzheimer's Disease

MT Newswires Live
·
Jun 16

Acumen nominates two development candidates in EBD program

TIPRANKS
·
Jun 16

Acumen nominates ACU301, ACU401 Enhanced Brain Delivery Alzheimer’s candidates, targets mid-2027 IND filing

Reuters
·
Jun 16

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (Ebd™) Development Candidates for the Treatment of Alzheimer’s Disease

THOMSON REUTERS
·
Jun 16

Acumen Pharma director Nathan B. Fountain sells 6,400 shares worth $14,273

Reuters
·
Jun 11

Acumen Stockholders Approve Directors and Equity Incentive Plan

TIPRANKS
·
Jun 04

Acumen Pharmaceuticals shareholders approve amended 2021 equity incentive plan

Reuters
·
Jun 04

Acumen Pharmaceuticals Warns Investors: Unchanged 10-K Risk Factors Still Weigh on Valuation and Share Price

TIPRANKS
·
May 14

Acumen Pharmaceuticals Bets Big on Alzheimer’s Trials

TIPRANKS
·
May 13

Acumen Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Acumen Pharmaceuticals posts corporate presentation on sabirnetug Alzheimer’s drug candidate

Reuters
·
May 12

Acumen Pharmaceuticals Q1 net loss narrows

Reuters
·
May 12

Acumen Pharmaceuticals Q1 EPS $(0.33) Beats $(0.36) Estimate

Benzinga Earnings
·
May 12

BRIEF-Acumen Pharmaceuticals, Inc. Q1 Income From Operations USD -21.149 Million

Reuters
·
May 12

Acumen Pharmaceuticals, Inc. Q1 Net Income USD -20.737 Million

THOMSON REUTERS
·
May 12